High avidity scFv multimers; diabodies and triabodies

Journal of Immunological Methods

Volumn 231, Issue 1-2, 1999, Pages 177-189

  Hudson, Peter J ^a   Kortt, Alexander A ^a  

^a CSIRO   (Australia)

Author keywords

Antibody engineering; Diabody; Dimers; Short linkers; Single chain Fvs; Triabody; Trimers

Indexed keywords

HAPTEN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; RECOMBINANT ANTIBODY;

ANTIBODY SPECIFICITY; ARTICLE; BINDING AFFINITY; CROSS LINKING; IMMUNOGLOBULIN VARIABLE REGION; PRIORITY JOURNAL; SERODIAGNOSIS; T LYMPHOCYTE;

ANIMALS; ANTIBODY AFFINITY; GENE EXPRESSION; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN VARIABLE REGION; RECOMBINANT FUSION PROTEINS;

EID: 0033506366     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(99)00157-X     Document Type: Article

References (67)

1. Adams, G.P., McCartney, J.E., Tai, M.-S., Opperman, H., Huston, J.S., Stafford, W.F., Bookman, M.A., Fand, I., Houston, L.L., Weiner, L.M., 1993. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res. 53, 4026-4034.
2. Adams, G.P., Schier, R., McCall, A.M., Crawford, R.S., Wolf, E.J., Weiner, L.M., Marks, J.D., 1998. Prolonged in vivo tumor retention of a human diabody targeting the extracellular domain of human HER2/neu. Br. J. Cancer 77, 1405-1412.
3. Adams, G.P. et al., 1999. Prolonged in vivo tumor retention of a human diabody targeting the extracellular domain of human HER2/neu. J. Immunol. Methods, this volume.
4. Antoniw, P., Farnsworth, A.P., Turner, A., Haines, A.M., Mountain, A., Mackintosh, J., Shochat, D., Humm, J., Welt, S., Old, L.J., Yarranton, G.T., King, D.J., 1996. Radioimmunotherapy of colorectal carcinoma xenografts in nude mice with yttrium-90 A33 IgG and Tri-Fab (TFM). Br. J. Cancer 74, 513-524.
5. Arndt, K.M., Muller, K.M., Pluckthun, A., 1998. Factors influencing the dimer to monomer transition of an antibody single-chain Fv fragment. Biochemistry 37, 12918-12926.
6. Atwell, J.L., Pearce, L.A., Lah, M., Gruen, L.C., Kortt, A.A., Hudson, P.J., 1996. Design and expression of a stable bispecific scFv dimer with affinity for both glycophorin and N9 neuraminidase. Molec. Immunology 33, 1301-1312.
7. L domains dictates precisely the transition between diabodies and triabodies. Protein Engineering 12, 597-604.
8. Bird, R.E., Hardman, K.D., Jacobson, J.W., Johnson, S., Kaufman, B.M., Lee, S.-L., Lee, T., Pope, S.H., Riodan, G.S., Whitlow, M., 1988. Single-chain antigen-binding proteins. Science 242, 423-426.
9. Brinkmann, U., Dicarlo, A., Vasmatzis, G., Kurochkina, N., Beers, R., Lee, B., Pastan, I., 1997. Stabilisation of a recombinant Fv fragment by base-loop interconnection and VH-VL permutation. J. Mol. Biol. 268, 107-117.
10. Casey, J.L., Keep, P.A., Chester, K.A., Robson, L., Hawkins, R.E., Begent, R.H., 1995. Purification of bacterially expressed single chain Fv antibodies for clinical applications using metal chelate chromatography. J. Immunol. Methods 179, 105-116.
11. Casey, J.L., King, D.J., Chaplin, L.C., Haines, A.M., Pedley, R.B., Mountain, A., Yarranton, G.T., Begent, R.H., 1996. Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments. Br. J. Cancer 74, 1397-1405.
12. Coia, G., Hudson, P.J., Lilley, G.G., 1996. Construction of recombinant extended single-chain antibody peptide conjugates for use in the diagnosis of HIV1 and HIV2. J. Immunol. Methods 192, 13-23.
13. Dall'Acqua, W., Carter, P., 1998. Antibody engineering. Curr. Opin. Struct. Biol. 8, 443-450.
14. Eshhar, Z., 1997. Tumor-specific T-bodies: towards clinical application. Cancer Immunol. Immunother. 45, 131.
15. Farah, R.A., Clinchy, B., Herrera, L., Vitetta, E.S., 1998. The development of monoclonal antibodies for the therapy of cancer. Crit. Rev. Eukaryotic Gene Expression 8, 321.
16. Fitzgerald, K., Holliger, P., Winter, G., 1997. Improved tumor targeting by disulphide stabilized diabodies expressed in Pichia pastoris. Protein Eng. 10, 1221.
17. Ghetie, M.A., Podar, E.M., Ilgen, Gordon, B.E., Uhr, J.W., Vitetta, E.S., 1997. Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells. Proc. Natl. Acad. Sci. USA 94, 7509-7514.
18. Helfrich, W., Kroesen, B.J., Roovers, R.C., Westers, L., Molema, G., Hoogenboom, H.R., De Leij, L., 1998. Construction and characterisation of a bispecific diabody for retargeting T-cells to human carcinomas. Int. J. Cancer 76, 232.
19. Holliger, P., Prospero, T., Winter, G., 1993. "Diabodies": small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. USA 90, 6444-6448.
20. Holliger, P., Brissinick, J., Williams, R.L., Thielemans, K., Winter, G., 1996. Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody. Protein Eng. 9, 299-305.
21. Holliger, P., Wing, M., Pound, J.D., Bohlen, H., Winter, G., 1997. Retargeting serum immunoglobulin with bispecific diabodies. Nature Biotechnology 15, 632-636.
22. Holliger, P., Manzke, O., Span, M., Hawkins, R., Fleischmann, B., Qinghua, L., Wolf, J., Diehl, V., Cochet, O., Winter, G., Bohlen, H.C., 1999. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 × anti-CEA bispecific diabodies and B7 × anti-CEA bispecific fusion proteins. Cancer Res. 59, 2909-2916.
23. Hudson, P.J., 1998. Recombinant antibody fragments. Curr. Opin. Biotech. 9, 395-402.
24. Hudson, P.J., 1999. Recombinant antibody constructs in cancer therapy. Curr. Opin. Immunol. 11 (5), 548-557.
25. Humphreys, D.P., Vetterlein, O.M., Chapman, A.P., King, D.J., Antoniw, P., Suitters, A.J., Reeks, D.G., Parton, T.A., King, L.M., Smith, B.J., Lang, V., Stephens, P.E., 1998. F(ab′)2 molecules made from Escherichia coli produced Fab' with hinge sequences conferring increased serum survival in an animal model. J. Immunol. Methods 217, 1.
26. Huston, J.S., Levinson, D., Mudgett-Hunter, M., Tai, M.S., Novotny, J., Margolies, M.N., Ridge, R.J., Bruccoleri, R.E., Haber, E., Crea, R., Opperman, H., 1988. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. USA 85, 5879-5883.
27. Iliades, P., Kortt, A.A., Hudson, P.J., 1997. Triabodies: single chain Fv fragments without a linker form trivalent trimers. FEBS Lett. 409, 437.
28. Kabat, E.A., Wu, T.T., Perry, H.M., Gottensman, K.S., Foeler, C., 1991. Sequences of Proteins of Immunological Interest. US Department of Health and Human Service, US Public Health service, NIH, Bethesda, MD.
29. Kipriyanov, S.M., Moldenhauer, G., Little, M., 1997. High level production of soluble single chain antibodies in small-scale Escherichia coli cultures. J. Immunol. Methods 200, 69-77.
30. Kipriyanov, S.M., Moldenhauer, G., Strauss, G., Little, M., 1998. Bispecific CD3XCD19 diabody for T cell-mediated lysis of malignant human B cells. Int. J. Cancer 77, 763.
31. Kontermann, R.E., Wing, M.G., Winter, G., 1997a. Complement recruitment using bispecific diabodies. Nature Biotechnolgy 15, 629.
32. Kontermann, R.E., Martineau, P., Cummings, C.E., Karpas, A., Allen, D., Derbyshire, E., Winter, G., 1997b. Enzyme immunoassays using bispecific diabodies. Immunotechnology 3, 137.
33. Kortt, A.A., Malby, R.L., Caldwell, J.B., Gruen, L.C., Ivancic, N.M., Lawrence, M.C., Howlett, G.J., Webster, R.G., Hudson, P.J., Colman, P.M., 1994. Recombinant antineuraminidase single chain Fv antibody: characterization, formation of dimer and higher molecular mass multimers and the solution of the crystal structure of the scFv-neuraminidase complex. Eur. J. Biochem. 221, 151-157.
34. Kortt, A.A., Lah, M., Oddie, G.W., Gruen, L.C., Burns, J.E., Pearce, L.A., Atwell, J.L., McCoy, A.J., Howlett, G.J., Metzger, D.W., Webster, R.G., Hudson, P.J., 1997. Single Chain Fv Fragments of anti-neuraminidase antibody NC10 containing five and ten residue linkers form dimers and with zero residue linker a trimer. Protein Eng. 10, 423-428.
35. Krebs, B., Ackermann, B., Rose-John, S., 1998. Specific targeting of cytokine-secreting cells: a bispecific diabody recognizing human interleukin-6 and CD3 induces T cell-mediated killing. J. Interferon Cytokine Res. 18, 783.
36. Lawrence, L.J., Kortt, A.A., Iliades, P., Tulloch, P.A., Hudson, P.J., 1998. Orientation of antigen binding sites in dimeric and trimeric single chain Fv antibody fragments. FEBS Lett. 425, 479-484.
37. Le Gall, F., Kipriyanov, S.M., Moldenhauer, G., Little, M., 1999. Di-, tri- and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding. FEBS Lett. 453, 164-168.
38. Malby, R.L., Caldwell, J.B., Gruen, L.C., Harley, V.R., Ivancic, N., Kortt, A.A., Lilley, G.G., Power, B.E., Webster, R.G., Colman, P.M., Hudson, P.J., 1993. Recombinant anti-neuraminidase single chain antibody: expression, characterisation and crystallisation in complex with antigen. Proteins 16, 57-63.
39. Malby, R.L., Tulip, W.R., Harley, V.R., McKimm-Breschkin, J.L., Laver, W.G., Webster, R.G., Colman, P.M., 1994. The structure of a complex between the NC10 antibody and influenza virus neuraminidase and comparison with the overlapping binding site of the NC41 antibody. Structure 2, 733-746.
40. Malby, R.L., McCoy, A.J., Kortt, A.A., Hudson, P.J., Colman, P.M., 1998. Single-chain fv/neuraminidase complexes: different stoichiometry in solution and crystals. J. Mol. Biol. 279, 901-910.
41. Manzke, O., Fitzgerald, K.J., Holliger, P., Klock, J., Span, M., Fleischmann, B., Hescheler, J., Qinghua, L., Johnson, K.S., Diehl, V., Hoogenboom, H.R., Bohlen, H., 1999. CD3 × antinitrophenyl bispecific diabodies: universal immunotherapeutic tools for retargeting T cells to tumors. Int. J. Cancer 82, 700-708.
42. McCartney, J.E., Tai, M.-S., Hudziak, R.M., Dams, G.P., Weiner, L.M., Jin, D., Stafford, W.F., Liu, S., Bookman, M.A., Laminet, A.A., Fand, I., Houston, L.L., Oppermann, H., Huston, J.S., 1995. Engineering disulfide-linked single-chain Fv dimers [(sFv′)2] with improved solution and targeting properties: anti-digoxin 26-10 (sFv′)2 and anti-c-erbB-2 741F8 (sFv′)2 made by protein folding and bonded through C-terminal cysteinyl peptides. Protein Eng. 8, 301-314.
43. McGuinness, B.T., Walter, G., Fitzgerald, K., Schuler, P., Mahoney, W., Duncan, A.R., Hoogenboom, H.R., 1996. Phage diabody repertoires for selection of large numbers of bispecific antibody fragments. Nature Biotechnolgy 14, 1149-1154.
44. Muller, K.M., Arndt, K.M., Pluckthun, A., 1998a. Model and simulation of multivalent binding to fixed ligands. Anal. Biochem. 261, 149.
45. Muller, K.M., Arndt, K.M., Pluckthun, A., 1998b. A dimeric bispecific miniantibody combines two specificities with avidity. FEBS Lett. 432 (1-2), 45-49.
46. Neri, D., Momo, M., Prospero, T., Winter, G., 1995. High-affinity antigen binding by chelating recombinant antibodies (CRAbs). J. Mol. Biol. 246, 367-373.
47. Pack, P., Muller, K., Zahn, R., Pluckthun, A., 1995. Tetravalent miniantibodies with high avidity assembling in Escherichia coli. J. Mol. Biol. 246, 28-34.
48. Pei, X.Y., Holliger, P., Murzin, A.G., Williams, R.L., 1997. The crystal structure of a trimeric antibody fragment with non-cognate VH-VL domain pairs shows a rearrangement of VH CDR3. Proc. Natl. Acad. Sci. USA 94, 9637.
49. Perisic, O., Webb, P.A., Holliger, P., Winter, G., Williams, R.L., 1994. Crystal structure of a diabody, a bivalent antibody fragment. Structure 2, 1217-1226.
50. Pluckthun, A., Pack, P., 1997. New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology 3, 83.
51. Power, B.E., Hudson, P.J., 1999. Design and expression of antibody fragments in E. coli. Methods Mol. Med. Cancer immunotherapy protocols. In press; (also available from authors on request).
52. Robert, B., Dorvillius, M., Buchegger, F., Garambois, V., Mani, J.C., Pugnieres, M., Mach, J.P., Pelegrin, A., 1999. Tumor targeting with newly designed biparatopic antibodies directed against two different epitopes of the carcinoembryonic antigen (CEA). Int. J. Cancer 81, 285-291.
53. Roux, K.H., Strelets, L., Michaelsen, T.E., 1997. Flexibility of human IgG subclasses. J. Immunol. 159, 3372-3382.
54. Roux, K.H., Strelets, L., Brekke, O.H., Sandlie, I., Michaelsen, T.E., 1998. Comparisons of the ability of human IgG3 hinge mutants, IgM, IgE, and IgA2, to form small immune complexes: a role for flexibility and geometry. J. Immunol. 161, 4083-4090.
55. Thouvenin, E., Laurent, S., Madelaine, M.F., Rasschaert, D., Vautherot, J.F., Hewat, E.A., 1997. Bivalent binding of a neutralising antibody to a calicivirus involves the torsional flexibility of the antibody hinge. J. Mol. Biol. 270, 238-246.
56. Turner, D.J., Ritter, M.A., George, A.J.T., 1997. Importance of the linker in expression of single-chain Fv antibody fragments-optimisation of peptide sequences using phage display technology. J. Immunol. Methods 205, 43.
57. Verma, R., Boleti, E., George, A.J.T., 1998. Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems. J. Immunol. Methods 216, 165.
58. Viti, F., Tarli, L., Giovannoni, L., Zardi, L., Neri, D., 1999. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res. 59, 347.
59. Watkins, S.J., Mesyanzhinov, V.V., Kurochkina, L.P., Hawkins, R.E., 1997. The 'adenobody' approach to viral targeting: specific and enhanced adenoviral gene delivery. Gene Therapy 4, 1004.
60. Whitlow, M., Filpula, D., Rollence, M.L., Feng, S.-L., Woods, J.F., 1994. Multivalent Fvs: characterisation of single chain Fv oligomers and preparation of a bispecific Fv. Protein Eng. 7, 1017-1026.
61. Wickham, T.J., Lee, G.M., Titus, J.A., Sconocchia, G., Bakacs, T., Kovesdi, I., Segal, D.M., 1997. Targeted adenovirus-mediated gene delivery to T cells via CD3. J. Virol. 71, 7663-7669.
62. Worn, A., Pluckthun, A., 1998. Mutual stabilization of VL and VH in single-chain antibody fragments, investigated with mutants engineered for stability. Biochemistry 37, 13120.
63. Wu, A.M., Chen, W., Raubitschek, A., Williams, L.E., Neumaier, M., Fischer, R., Hu, S.-Z., Odom-Maryon, T., Wong, J.Y.C., Shively, J.E., 1996. Tumor localisation of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers. Immunotechnology 2, 21-36.
64. Wu, A.M., Williams, L.E., Zieran, L., Padma, A., Sherman, M., Bebb, G.G., Odom-Maryon, T., Wong, J.Y.C., Shively, J.E., Raubitschek, A.A., 1999. Anti-carcinoembryonic antigen (CEA) diabody for rapid tumor targeting and imaging. Tumor Targeting 4, 47-58.
65. Zdanov, A., Li, Y., Bundle, D.R., Deng, S.-J., MacKenzie, C.R., Narang, S.A., Young, N.M., Cygler, M., 1994. Structure of a single-chain antibody variable domain (Fv) fragment complexed with a carbohydrate antigen at 1.7-A resolution. Proc. Natl. Acad. Sci. USA 91, 6423-6427.
66. Zhu, Z., Zapata, G., Shalaby, R., Snedecor, B., Chen, H., Carter, P., 1996. High level secretion of a humanised bispecific diabody from E. coli. Nature Biotechnology 14, 192.
67. Zhu, Z., Presta, L.G., Zapata, G., Carter, P., 1997. Remodeling domain interfaces to enhance heterodimer formation. Protein Sci. 6, 781-788.